Compare Two Stocks
Valuation, growth, earnings reaction and guidance credibility, side by sideALNYAlnylam Pharmaceuticals
FinDog View：Neutral
| Metric | ABBV | ALNY |
|---|
| Close | 281.12 | 227.02 |
| Market Cap | $489B | $31.1B |
| 1M | +9.33% | −8.71% |
| P/E (TTM) | 77.4 | 38.5 |
| Forward P/E | 16.9 | 28.0 |
| P/E 5-Yr Percentile | 55 | — |
| P/S | 7.6 | 6.5 |
| P/B | — | 23.0 |
| Dividend Yield | 4.47% | — |
| Latest Quarter Revenue | $17.0B | $1.3B |
| Revenue YoY | +10.2% | +66.9% |
| Gross Margin | 74.7% | 76.9% |
| Latest Quarter EPS | 2.03 | 1.21 |
| Avg Post-Earnings Move | ±1.7% | ±1.7% |
| EPS Beat Rate | — | — |
| Guidance Hit Rate | — | — |
| Shareholder Yield | 2.76% | — |
| 90-Day Net Insider Buying | −$8.2M | −$0.40M |
ABBV · Revenue, Last 8 Quarters ($B)
ALNY · Revenue, Last 8 Quarters ($B)
